(Q34963971)

5 August 2017

What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models (English)

1 reference

5 August 2017

1 reference

David F Penson

4

0 references

author name string

Roman Gulati

1

1 reference

5 August 2017

Elisabeth M Wever

2

1 reference

5 August 2017

Alex Tsodikov

3

1 reference

5 August 2017

Lurdes Y T Inoue

5

1 reference

5 August 2017

Jeffrey Katcher

6

1 reference

5 August 2017

Shih-Yuan Lee

7

1 reference

5 August 2017

Eveline A M Heijnsdijk

8

1 reference

5 August 2017

Gerrit Draisma

9

1 reference

5 August 2017

Harry J de Koning

10

1 reference

5 August 2017

Ruth Etzioni

11

1 reference

5 August 2017

1 May 2011

1 reference

Cancer Epidemiology, Biomarkers & Prevention

5 August 2017

1 reference

5 August 2017

20

1 reference

5 August 2017

5

1 reference

5 August 2017

740-750

1 reference

Modeling Disease Progression with Longitudinal Markers

5 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

Calibrating disease progression models using population data: a critical precursor to policy development in cancer control

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

Stage-specific cancer incidence: an artificially mixed multinomial logit model

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

Screening and prostate-cancer mortality in a randomized European study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

Mortality results from a randomized prostate-cancer screening trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

Quantifying the role of PSA screening in the US prostate cancer mortality decline

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

Radical prostatectomy versus watchful waiting in early prostate cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

20-year outcomes following conservative management of clinically localized prostate cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

The influence of finasteride on the development of prostate cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

Prostate cancer and the Will Rogers phenomenon.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

Combining longitudinal studies of PSA.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

Natural History of Early, Localized Prostate Cancer

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

Asymptomatic incidence and duration of prostate cancer

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3091266

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer

26 October 2018

1 reference

12 December 2020

A population model of prostate cancer incidence

1 reference

12 December 2020

Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing

1 reference

12 December 2020

Survival prospects after screen-detection of prostate cancer

1 reference

12 December 2020

Gleason score, age and screening: Modeling dedifferentiation in prostate cancer

1 reference

12 December 2020

Predicting survival for men with clinically localized prostate cancer: what do we need in contemporary practice?

1 reference

12 December 2020

Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach

1 reference

12 December 2020

10.1158/1055-9965.EPI-10-0718

Identifiers

DOI

1 reference

5 August 2017

1 reference

5 August 2017

1 reference